Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 11/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30140439 | 0.92 | EGFR (0.55) | GPR119EGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL30140259 | 0.88 | EGFR (0.48) | GPR119EGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL30140282 | 0.88 | GPR119 (0.50) | GPR119EGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL30140064 | 0.87 | EGFR (0.61) | EGFRERBB2 | |
| SCHEMBL30140275 | 0.87 | EGFR (0.48) | GPR119EGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL30140225 | 0.87 | GPR119 (0.49) | GPR119EGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL30140427 | 0.87 | GPR119 (0.49) | GPR119EGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL30140148 | 0.86 | EGFR (0.54) | GPR119EGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL30140428 | 0.86 | EGFR (0.47) | GPR119EGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL30140204 | 0.86 | EGFR (0.46) | GPR119EGFRERBB2PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266426-A1 | 6-(HETEROCYCLOALKYL-OXY)-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |